secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001171843-25-005180
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Q2 net loss $8M, cash $74.4M; soquelitinib atopic dermatitis data shows deeper EASI reduction
--------------------------------------------------------------------------------

- Net loss $8.0M for Q2 2025 vs $4.3M Q2 2024; R&D expenses $7.9M (up from $4.1M).
- Cash, equivalents, securities $74.4M as of June 30, 2025; warrant exercise proceeds $35.7M in Q2.
- Soquelitinib Phase 1 atopic dermatitis: cohort 3 mean EASI reduction 64.8% at day 28 vs 54.6% for cohorts 1-2 and 34.4% placebo.
- 50% of evaluable cohort 3 patients had ≥4 point itch reduction (PP-NRS) at day 28; Phase 2 on track by year-end.
- Phase 3 PTCL registrational trial enrolling; cash expected to fund operations into Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184325005180/0001171843-25-005180-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184325005180/f8k_080725.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005180

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer